Targeting sellers of substitute products such as Hims & Hers
"To protect consumers...legal action for violations"

The U.S. Food and Drug Administration (FDA) has banned the sale of low-cost substitute products compounded with the same ingredient as the oral obesity drug Wegovy.


On the 7th (local time), FDA Commissioner Martin Makary said, "We will take firm measures to ensure that the active ingredient of the obesity treatment glucagon-like peptide-1 (GLP-1) is not used in compounded drugs that are mass-marketed." He went on to point out, "Telehealth companies such as Hims & Hers are conducting large-scale marketing campaigns that promote compounded drugs, which have not been approved by the FDA, as if they were alternative versions similar to FDA-approved drugs." Hims & Hers is a telehealth company headquartered in San Francisco, United States.


U.S. FDA Bans Sales of Unapproved Wegovy-Like Products View original image

Commissioner Makary stressed, "Companies cannot advertise compounded products that have not been approved by the FDA as generics or as the same products as FDA-approved drugs," adding, "They also cannot state that compounded drugs use the same active ingredient as FDA-approved drugs." He warned that if companies do not properly correct violations, the agency plans to take additional legal actions beyond seizure and injunction orders.


The FDA's announcement came just one day after Hims & Hers said it would launch at a low price a compounded product that contains the same active ingredient as Danish pharmaceutical company Novo Nordisk's oral Wegovy tablet. On the 5th, when announcing the product launch, Hims & Hers introduced it by saying, "This once-daily pill contains the same active ingredient as Wegovy." The company released the product using a compounding method that customizes the dosage of existing pharmaceutical ingredients to meet the needs of individual patients. The FDA allows compounding for patient-specific prescriptions without separate approval.



In early January, Novo Nordisk began selling the oral tablet form of Wegovy in the U.S. market. The price of the original Wegovy product was set at a minimum of 149 dollars per month (about 220,000 won), while Hims & Hers announced that it plans to sell its product for 49 dollars per month (about 70,000 won) in the first month after launch and 99 dollars per month (about 140,000 won) thereafter. The way Hims & Hers sells its compounded drug, which has not been approved by the FDA, through large-scale online marketing has sparked controversy over both safety and legality.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing